{"entity":{"id":"nature-biotechnology","kind":"journal","name":"Nature Biotechnology","aka":["Nat Biotechnol"],"tldr":"Nature Biotechnology is the leading biotechnology journal, covering new sequencing and single-cell methods, CAR-T and gene-editing engineering, ADC and protein design, plus biotech industry analysis.","summary":"Nature Biotechnology (Nat Biotechnol) is the leading biotechnology journal, founded in 1983, appearing monthly and published by Springer Nature on a hybrid access model. It publishes methods and tools such as single-cell and spatial omics, base and prime editing and protein design, together with engineered therapeutics including next-generation CAR-T cells, bispecifics and ADCs, and its news section tracks the biotech industry and regulation. Its readers are technologists, cell and gene therapy engineers and industry watchers. Within OnCo it is linked from the Andreas Trumpp biography, and a reader would use it for new sequencing and single-cell methods and for the engineering behind cell therapies and antibody constructs.","asOf":"2026-09-09","links":[{"label":"Nature Portfolio","url":"https://www.nature.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["genomic-profiling"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature","url":"https://www.nature.com/nbt/","issn":"1087-0156","scope":"biotechnology","access":"hybrid","founded":1983,"matchNames":["Nature Biotechnology","Nat Biotechnol"]},"route":"/journals/nature-biotechnology/","neighbours":{"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"term":[{"id":"genomic-profiling","kind":"term","name":"Genomic profiling","route":"/terms/genomic-profiling/"}],"person":[{"id":"andreas-trumpp","kind":"person","name":"Andreas Trumpp","route":"/people/andreas-trumpp/"}],"paper":[{"id":"paper-doronina-nat-biotechnol","kind":"paper","name":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","route":"/key-papers/paper-doronina-nat-biotechnol/"},{"id":"paper-kurtz-nat-biotechnol","kind":"paper","name":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","route":"/key-papers/paper-kurtz-nat-biotechnol/"},{"id":"paper-klichinsky-nat-biotechnol","kind":"paper","name":"Human chimeric antigen receptor macrophages for cancer immunotherapy","route":"/key-papers/paper-klichinsky-nat-biotechnol/"},{"id":"paper-roohani-nat-biotechnol","kind":"paper","name":"Predicting transcriptional outcomes of novel multigene perturbations with GEARS","route":"/key-papers/paper-roohani-nat-biotechnol/"},{"id":"paper-russell-peng-bell-oncolytic-virotherapy-natbiotech-2012","kind":"paper","name":"Russell, Peng and Bell 2012: the field states its own problems","route":"/key-papers/paper-russell-peng-bell-oncolytic-virotherapy-natbiotech-2012/"}]}}